243 related articles for article (PubMed ID: 30485860)
1. Clinicopathological Profiling of Lung Carcinoids with a Ki67 Index > 20.
Kasajima A; Konukiewitz B; Oka N; Suzuki H; Sakurada A; Okada Y; Kameya T; Ishikawa Y; Sasano H; Weichert W; Klöppel G
Neuroendocrinology; 2019; 108(2):109-120. PubMed ID: 30485860
[TBL] [Abstract][Full Text] [Related]
2. Classification and Prognostic Stratification of Bronchopulmonary Neuroendocrine Neoplasms.
Oka N; Kasajima A; Konukiewitz B; Sakurada A; Okada Y; Kameya T; Weichert W; Ishikawa Y; Suzuki H; Sasano H; Klöppel G
Neuroendocrinology; 2020; 110(5):393-403. PubMed ID: 31422400
[TBL] [Abstract][Full Text] [Related]
3. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
[TBL] [Abstract][Full Text] [Related]
4. Alterations in Ki67 Labeling Following Treatment of Poorly Differentiated Neuroendocrine Carcinomas: A Potential Diagnostic Pitfall.
Vyas M; Tang LH; Rekhtman N; Klimstra DS
Am J Surg Pathol; 2021 Jan; 45(1):25-34. PubMed ID: 33177340
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications.
Klöppel G
Visc Med; 2017 Oct; 33(5):324-330. PubMed ID: 29177160
[TBL] [Abstract][Full Text] [Related]
6. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
7. Long Non-coding RNAs in Pulmonary Neuroendocrine Neoplasms.
Narayanan D; Mandal R; Hardin H; Chanana V; Schwalbe M; Rosenbaum J; Buehler D; Lloyd RV
Endocr Pathol; 2020 Sep; 31(3):254-263. PubMed ID: 32388776
[TBL] [Abstract][Full Text] [Related]
8. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors.
Walts AE; Ines D; Marchevsky AM
Mod Pathol; 2012 Sep; 25(9):1258-64. PubMed ID: 22575865
[TBL] [Abstract][Full Text] [Related]
9. Molecular markers help characterize neuroendocrine lung tumors.
Rusch VW; Klimstra DS; Venkatraman ES
Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
[TBL] [Abstract][Full Text] [Related]
10. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity.
Laitinen KL; Soini Y; Mattila J; Pääkkö P
Cancer; 2000 Apr; 88(7):1590-8. PubMed ID: 10738217
[TBL] [Abstract][Full Text] [Related]
11. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
12. PDGFRα expression as a novel therapeutic marker in well-differentiated neuroendocrine tumors.
Cavalcanti E; Ignazzi A; De Michele F; Caruso ML
Cancer Biol Ther; 2019; 20(4):423-430. PubMed ID: 30346879
[TBL] [Abstract][Full Text] [Related]
13. Proliferation Marker (Ki67) in Sub-Categorization of Neuroendocrine Tumours of the Lung.
Garg R; Bal A; DAS A; Singh N; Singh H
Turk Patoloji Derg; 2019; 35(1):15-21. PubMed ID: 30070306
[TBL] [Abstract][Full Text] [Related]
14. Lung and digestive neuroendocrine neoplasms. From WHO classification to biomarker screening: Which perspectives?
Scoazec JY
Ann Endocrinol (Paris); 2019 Jun; 80(3):163-165. PubMed ID: 31064659
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
[TBL] [Abstract][Full Text] [Related]
16. Tumor characteristics, expressions of ERCC1, Bax, p53, IGF1R, Bcl2, Bcl2/Bax and prognostic factors for overall survival in patients with lung carcinoid.
Velinovic M; Jankovic R; Jovanovic D; Skodric Trifunovic V; Gavrilovic D; Stojsic J; Cavic M
J BUON; 2019; 24(1):256-266. PubMed ID: 30941978
[TBL] [Abstract][Full Text] [Related]
17. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms.
Panzuto F; Cicchese N; Partelli S; Rinzivillo M; Capurso G; Merola E; Manzoni M; Pucci E; Iannicelli E; Pilozzi E; Rossi M; Doglioni C; Falconi M; Delle Fave G
PLoS One; 2017; 12(6):e0179445. PubMed ID: 28644861
[TBL] [Abstract][Full Text] [Related]
18. Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.
Rekhtman N; Desmeules P; Litvak AM; Pietanza MC; Santos-Zabala ML; Ni A; Montecalvo J; Chang JC; Beras A; Preeshagul IR; Sabari JK; Rudin CM; Ladanyi M; Klimstra DS; Travis WD; Lai WC
Mod Pathol; 2019 Jul; 32(8):1106-1122. PubMed ID: 30923345
[TBL] [Abstract][Full Text] [Related]
19. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.
Klöppel G; La Rosa S
Virchows Arch; 2018 Mar; 472(3):341-349. PubMed ID: 29134440
[TBL] [Abstract][Full Text] [Related]
20. [Consensus and controversy on subtype classification of gastric neuroendocrine neoplasms].
Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):977-981. PubMed ID: 28900986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]